|
1
|
Welcsh PL, Owens KN and King MC: Insights
into the functions of BRCA1 and BRCA2. Trends Genet. 16:69–74.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bergman A, Flodin A, Engwall Y, Arkblad
EL, Berg K and Nordling M, Martinsson T, Wahlström J, Karlsson P
and Nordling M: A high frequency of germline BRCA1/2 mutations in
western Sweden detected with complementary screening techniques.
Fam Cancer. 4:89–96. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang J, Pei R, Pang Z, Ouyang T, Li J,
Wang T, Fan Z, Fan T, Lin B and Xie Y: Prevalence and
characterization of BRCA1 and BRCA2 germline mutations in Chinese
women with familial breast cancer. Breast Cancer Res Treat.
132:421–428. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mullan PB, Quinn JE and Harkin DP: The
role of BRCA1 in transcriptional regulation and cell cycle control.
Oncogene. 25:5854–5863. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Baer R and Ludwig T: The BRCA1/BARD1
heterodimer, a tumor suppressor complex with ubiquitin E3 ligase
activity. Curr Opin Genet Dev. 12:86–91. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moynahan ME and Jasin M: Mitotic
homologous recombination maintains genomic stability and suppresses
tumorigenesis. Nat Rev Mol Cell Biol. 11:196–207. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shakya R, Reid LJ, Reczek CR, Cole F, Egli
D, Lin CS, deRooij DG, Hirsch S, Ravi K, Hicks JB, et al: BRCA1
tumor suppression depends on BRCT phosphoprotein binding, but not
its E3 ligase activity. Science. 334:525–528. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Linger RJ and Kruk PA: BRCA1 16 years
later: Risk-associated BRCA1 mutations and their functional
implications. FEBS J. 277:3086–3096. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Konishi H, Mohseni M, Tamaki A, Garay JP,
Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, et
al: Mutation of a single allele of the cancer susceptibility gene
BRCA1 leads to genomic instability in human breast epithelial
cells. Proc Natl Acad Sci USA. 108:17773–17778. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Figge MA and Blankenship L: Missense
mutations in the BRCT domain of BRCA-1 from high-risk women
frequently perturb strongly hydrophobic amino acids conserved among
mammals. Cancer Epidemiol Biomarkers Prev. 13:1037–1041.
2004.PubMed/NCBI
|
|
11
|
Easton DF, Deffenbaugh AM, Pruss D, Frye
C, Wenstrup RJ, Allen-Brady K, Tavtigian SV, Monteiro AN, Iversen
ES, Couch FJ and Goldgar DE: A systematic genetic assessment of
1,433 sequence variants of unknown clinical significance in the
BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet.
81:873–883. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Foulkes WD and Shuen AY: In brief: BRCA1
and BRCA2. J Pathol. 230:347–349. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pohlreich P, Zikan M, Stribrna J, Kleibl
Z, Janatova M, Kotlas J, Zidovska J, Novotny J, Petruzelka L, Szabo
C and Matous B: High proportion of recurrent germline mutations in
the BRCA1 gene in breast and ovarian cancer patients from the
Prague area. Breast Cancer Res. 7:R728–R736. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Walsh T, Casadei S, Coats KH, Swisher E,
Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, et
al: Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in
families at high risk of breast cancer. JAMA. 295:1379–1388. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kwong A, Ng EK, Tang EY, Wong CL, Law FB,
Leung CP, Chan A, Cheung MT, To MY, Ma ES, et al: A novel de novo
BRCA1 mutation in a Chinese woman with early onset breast cancer.
Fam Cancer. 10:233–237. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Neamatzadeh H, Shiryazdi SM and Kalantar
SM: BRCA1 and BRCA2 mutations in Iranian breast cancer patients: A
systematic review. J Res Med Sci. 20:284–293. 2015.PubMed/NCBI
|
|
18
|
Moynahan ME and Jasin M: Mitotic
homologous recombination maintains genomic stability and suppresses
tumorigenesis. Nat Rev Mol Cell Biol. 11:196–207. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huen MS, Sy SM and Chen J: BRCA1 and its
toolbox for the maintenance of genome integrity. Nat Rev Mol Cell
Biol. 11:138–148. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Satoh MS and Lindahl T: Role of
poly(ADP-ribose) formation in DNA repair. Nature. 356:356–358.
1992. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fong PC, Boss DS, Yap TA, Tutt A, Wu P,
Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, et
al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA
mutation carriers. N Engl J Med. 361:123–134. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guha M: PARP inhibitors stumble in breast
cancer. Nat Biotechnol. 29:373–374. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee JM, Ledermann JA and Kohn EC: PARP
Inhibitors for BRCA1/2 mutation-associated and BRCA-like
malignancies. Ann Oncol. 25:32–40. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bixel K and Hays JL: Olaparib in the
management of ovarian cancer. Pharmgenomics Pers Med. 8:127–135.
2015.PubMed/NCBI
|
